参考文献/References:
[1] Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults.Executive summary of the third report of the National cholesterol education program(NCEP)expert panel on detection, evaluation, and treatment of high blood cholesterol in adults(adult treatment panel III)[J].JAMA,2001,285(19):2486-2497.
[2] 中国成人血脂异常防治指南制订联合委员会.中国成人血脂异常防治指南[J].中国实用乡村医生杂志,2012,19(18):5-15.
[3] Cannon P,Braunwald Eugene,Mccabe H,et al.Intensive versus moderate lipid lowering with statins after acute coronary syndromes[J].N Engl J Med,2004,350(15):1495-1504.
[4] Baigent C,Keech A,Kearney PM,et al.Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins[J].Lancet,2005,366(9493):1267-1278.
[5] Cholesterol Treatment Trialists'(CTT)Collaborators,Kearney M,Blackwell L,et al.Efficacy of cholesterol-lowering therapy in 18,686 People with diabetes in 14 randomised trials of statins: a meta-analysis[J].Lancet,2008,371(967):117-125.
[6] Sniderman Allan,Mcqueen Matt,Contois John,et al.Why is non-high-density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoprotein cholesterol?[J].J Clin Lipidol,2010,4(3):152-155.
[7] Gonghuan,Yang Y.Rapid health transition in China[J].findings from the Global Burden of Disease Study 2010.Lancet,2013,381(9882):1987-2015.
[8] Chei CL,Yamagishi K.CIRCS investigators[J].High.density lipoprotein subclasses and risk of stroke and its subtypes in Japanese population:the Circulatory Risk in Communities Study.Stroke,2013,44:327-333.
[9] Ballantyne M,Raichlen S,Cain A.Statin therapy alters the relationship between apolipoprotein B and low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol targets in high-risk patients: the Mercury II(Measuring Effective Reductions in Cholesterol Using Rosuvastatin)trial[J].J Am Coll Cardiol,2008,52(8):626-632.
[10] National Cholesterol Education Program Expert Panel.Executive summary of the third report of the National Cholesterol Education Program(NCEP)Expert Panel on detection,evaluation,and treatment of high blood cholesterol in adults(Adults Treatment Panel III)[J].JAMA,2001,285:2486-2497.
[11] Stone NJ,Robinson JG,Lichtenstein AH,et al.2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults a report of the American college of cardiology/American heart association task force on practice guidelines[J].J Am Coll Cardiol,2014,63(25, B):2889-2934.
[12] Pischon T,Girman CJ,Sacks FM,et al.Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men[J].Circulation,2005,112(22):3375-3383.
[13] Arsenault BJ,Rana JS,Stroes ES,et al.Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healt[J].J Am Coll Cardiol,2009,55(1):35-41.
[14] 许海燕; 乔树宾; 张家芬.非高密度脂蛋白胆固醇对冠状动脉病变的影响[J].中国动脉硬化杂志,2010,18(5):409-411.
[15] Imamura T,Doi Y,Ninomiya T,et al.Non-high-density lipoprotein cholesterol and the development of coronary heart disease and stroke subtypes in a general Japanese population: the Hisayama Study[J].Atherosclerosis,2014,233(2):343-348.
[16] Wu Jianwei,Chen Shengyun,Zhou Yong,et al.Non-high-density lipoprotein cholesterol on the risks of stroke: a result from the Kailuan study[J].PLoS One,2013,8(9):e74634.
[17] Emerging Risk Factors Collaboration,Di Angelantonio E,Sarwar N,et al.Major lipids, apolipoproteins, and risk of vascular disease[J].JAMA,2009,302(18):1993-2000.
[18] Tanabe Naohito,Iso Hiroyasu,Okada Katsutoshi,et al.Serum total and non-high-density lipoprotein cholesterol and the risk prediction of cardiovascular events-the JALS-ECC -[J].Circ J,2010,74(7):1346-1356.